Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

NCT00606645 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
23
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Xencor, Inc.